Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes - sprookjes - yvandenbroek - TriplyDB

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

http://www.wikidata.org/entity/Q28188162

about

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Probucol for type 2 diabetes mellitus Calcium channel blockers versus other classes of drugs for hypertension Probucol for type 2 diabetes mellitus Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease Angiotensin receptor blockers and myocardial infarction Standards of medical care in diabetes--2012 Avosentan reduces albumin excretion in diabetics with macroalbuminuria Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy Guidelines for the management of chronic kidney disease Polymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patients Losartan and diabetic nephropathy: commentaries on the RENAAL study A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease Recent advances in managing and understanding diabetic nephropathy Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Interdisciplinary care clinics in chronic kidney disease The kallikrein-kinin system in diabetic nephropathy Hypertension and chronic kidney disease: controversies in pathogenesis and treatment Cell biology and pathology of podocytes Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis Present and future in the treatment of diabetic kidney disease Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system Sulodexide and glycosaminoglycans in the progression of renal disease MicroRNAs in Diabetic Kidney Disease Calcium channel blockers Obesity and kidney protection Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents Diabetic kidney disease: a report from an ADA Consensus Conference Diabetes and end-stage renal disease; a review article on new concepts

P2860

Q22241786-354255F2-3FCD-4B93-A114-DEFB71B8FDA7 Q24186039-A057CB9A-748F-46C0-867F-F0658371FB1F Q24186647-A6D76B46-8BA2-47C9-96E6-32166A47B279 Q24195163-0A488515-BBC9-4C4F-8675-B620EC35BBFF Q24236584-05C3A6CF-016A-4D5B-99CC-285FA7B401DB Q24240606-9AF7625A-DCA9-41E7-B77A-5B886F5E2596 Q24244197-5EEBA10D-B0DF-4085-9CA7-A874C370DCE7 Q24320230-7E06F4BE-F572-4D73-A46D-326A490CCD1B Q24559659-311C375C-C7AE-49CE-B351-500F14345C75 Q24632533-610AB9C9-CF7F-4B62-8849-ABD67303285D Q24642372-F337A098-665B-4CA2-B9B6-B2D991DDFC4A Q24652838-038F682F-017E-4711-B95F-2BA91353DF72 Q24657470-4832D4FE-18FA-452F-B29B-96AD1325AAAE Q24657844-25B5614D-D5EF-4E9E-A228-A42165DF46C3 Q24658206-354C0608-38A4-4481-BC14-27A3339655A2 Q24796010-8B08E407-3604-43E3-BC9C-6AB7CAC8BCB4 Q24806038-741739CE-1A72-4C5D-BECE-0159D4F3DD39 Q24814563-2252C842-9E41-4891-A472-F8B776E9FD16 Q26740125-72D24379-5A90-4360-BF64-C115A4C09BE6 Q26745900-EFDD7F54-E4B3-4CF1-B416-30AD95A14C16 Q26766025-78076CDF-3DA0-4265-AD97-1689EA38953D Q26766599-3D4D7929-A49A-452A-A61F-26DFD5E75F27 Q26767011-3781FF53-03CE-4993-9F24-3C49D7AEC4FE Q26767278-053C15AB-3390-4FD3-9103-D9C64DBE4E83 Q26768696-DDBBC1D9-2D71-42C6-892C-A96C58170336 Q26784077-1999D025-A259-4F83-8A34-6EB2EA99EAF0 Q26827473-24A27D4A-A53B-4968-BB91-D86927364A09 Q26851271-61B179FF-DD53-42CB-994B-DAFB885501FF Q26853664-0BA61FA3-41B0-461B-80A7-76C97C4E245C Q26863404-101AA626-137B-42F2-A99E-E2A22B75B407 Q26864133-B77FC9CF-DEA8-4B63-B52F-07B559FFDCA7 Q26865691-3DBBF51B-84CC-4846-9C4F-A0BCA7665B73 Q26991825-B0683428-90A7-4B24-BCFA-85FBF8B46C95 Q27002171-01F83C48-1963-4D78-B78E-83347B2B77B3 Q27003120-AED8A5B4-14B8-4EEC-A898-0E6600281641 Q27005818-2E432736-C01B-4685-A0A8-9B43F88F02C9 Q27007027-CAE1DA99-681E-4C43-9E52-1E3BE879FD20 Q27010669-F71CCD05-10DB-4F98-8D8E-2E4967EAB02B Q27012546-7B5033D8-1E4E-46B0-949B-A114002ED257 Q27023025-7F8E430A-AFD1-4438-BC0B-0170A45811A4

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

http://www.wikidata.org/entity/Q28188162

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@ast

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@en

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@nl

type

label

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@ast

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@en

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@nl

prefLabel

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@ast

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@en

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@nl

P1433

Q28188162-39D49ADD-EF09-4A6C-8873-8A89580887C3

P1476

Q28188162-93BE7EDA-6999-4B9A-93B6-5CE81682A295

P2093

Q28188162-32A9F8A0-7C06-4C01-8E72-ED058339331A

Q28188162-6DA0AD41-B756-4EFA-AC6E-CA627BC42403

Q28188162-6F400E83-87F1-4946-95BA-F9E838E5DBE5

Q28188162-8EE346C8-4565-4064-8881-C414B2F171DB

Q28188162-94015C03-8B7C-4C78-B43F-999A0086AFF3

Q28188162-96E302B9-5DD5-4BB0-9458-3200B3B62279

Q28188162-C0D6C7C9-8D1C-41C2-936B-DDDB924F312A

Q28188162-D9F53284-3EB2-418A-BE7B-C27E92E347F8

Q28188162-F5116070-26D3-483B-B886-446844FC382E

Q28188162-FE3C6465-D4C2-4A2E-8B4E-F32BF645DCCE

P304

Q28188162-3A802664-C17D-4290-8799-3E1A94466B08

P31

Q28188162-3F5BC3AE-717F-4BF0-87AF-3A599CCAF7BA

P3181

Q28188162-8A73D12B-FC96-4AFC-9B59-0B5BFEF8249A

P356

Q28188162-5B53618B-B6C2-46BC-BE10-F15638538023

P407

Q28188162-3DD4642F-74E1-4BEE-B785-DE4236BE0293

P433

Q28188162-0905A236-DF86-4950-9AB6-A9A1165BB262

P478

Q28188162-BCD56AD5-6D00-451B-A21F-8ED5BADDDB7C

P577

Q28188162-9302F441-9900-448A-9825-C6436A4D86BC

P698

Q28188162-D84F65EC-9D08-4E1F-99EC-F1B36F0119DE

P921

Q28188162-84F6C79C-A1A4-41ED-B072-609B9F9A6F4C

Q28188162-DA8C12B0-8355-4663-B693-51188BD2ACE8

P3181

P356

P1433

The New England Journal of Medicine

P1476

Renoprotective effect of the a ...... ropathy due to type 2 diabetes

@en

P2093

E J Lewis

http://www.w3.org/2001/XMLSchema#string

E Ritz

http://www.w3.org/2001/XMLSchema#string

I Raz

http://www.w3.org/2001/XMLSchema#string

J B Lewis

http://www.w3.org/2001/XMLSchema#string

L G Hunsicker

http://www.w3.org/2001/XMLSchema#string

M A Pohl

http://www.w3.org/2001/XMLSchema#string

R C Atkins

http://www.w3.org/2001/XMLSchema#string

R Rohde

http://www.w3.org/2001/XMLSchema#string

T Berl

http://www.w3.org/2001/XMLSchema#string

W R Clarke

http://www.w3.org/2001/XMLSchema#string

P304

851-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

634274

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA011303

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11565517

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes